Literature DB >> 16039851

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

Tom D Heightman1, Laramie M Gaster, Sarah L Pardoe, Jean-Pierre Pilleux, Michael S Hadley, Derek N Middlemiss, Gary W Price, Claire Roberts, Claire M Scott, Jeannette M Watson, Laurie J Gordon, Vicky A Holland, Jenifer Powles, Graham J Riley, Tania O Stean, Brenda K Trail, Neil Upton, Nigel E Austin, Andrew D Ayrton, Tanya Coleman, Leanne Cutler.   

Abstract

The novel 8-piperazinyl-2,3-dihydropyrroloisoquinoline template was synthesized in nine steps. The template was N-substituted to give a series of compounds showing binding to human cloned 5-HT1A, 5-HT1B and 5-HT1D receptors with pKi's greater than 9 and selectivities up to 1000-fold against other serotonin, dopamine and adrenergic receptors. Several compounds were shown to possess weak partial agonist activity in cloned receptors, which translated to antagonism in in vitro studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039851     DOI: 10.1016/j.bmcl.2005.06.042

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Classification of 5-HT(1A) receptor agonists and antagonists using GA-SVM method.

Authors:  Xue-lian Zhu; Hai-yan Cai; Zhi-jian Xu; Yong Wang; He-yao Wang; Ao Zhang; Wei-liang Zhu
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

Review 2.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.